2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study. (September 2015) - Necchi, A.